Actively Recruiting
Phase 4 Study of Tirzepatide to Evaluate Safety and Effectiveness in Adult Indian Patients With Type 2 Diabetes or Obesity Over 46 Weeks
Led by Eli Lilly and Company · Updated on 2026-05-19
344
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of tirzepatide in adult participants in India who either have type 2 diabetes or are obese or overweight without type 2 diabetes. This phase 4, open-label study aims to understand how tirzepatide works in these groups over approximately 46 weeks. Participants will receive tirzepatide administered by subcutaneous injection. The study includes one treatment arm where all participants receive this medication. Research will focus on tracking serious adverse events related to the drug, as well as changes in body weight, blood sugar control HbA1c, and waist size over the study period. During the 46 weeks of participation, individuals will have regular visits for safety monitoring and assessments. Researchers will measure serious side effects, body weight reduction, HbA1c levels for those with diabetes, and waist circumference changes. This detailed monitoring helps evaluate the drugs impact and gather safety data throughout the treatment period.
CONDITIONS
Brief Title
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
